DrugRepV Browse Page

DrugRepV browse page allows user to take a glance of the particular antiviral agent.Fields in the webpage is hylerlinked ot various external repositories like DrugBank, PubChem, Clinicaltrials.gov,and PubMed.User can explore the biological, Clinical, Chemical, and Structural details of every repurposed drug candidate.By clicking on the table header arrows, user can sort entries in ascending or descending order.


Total number of Records for qRT-PCR are 57

DrugRepV_ID	Antiviral Name	Drug type	Primary Indication	Secondary Indication	Strain	Pathways	Assay	Activity	Clinical Status	References
DrugRepV_3623	Benzodiazepine	Nervous System	Obesity, Sleep Apnea, Obstructive, and Disorders of Gallbladder, Biliary Tract and Pancrease.	Rift Valley fever virus	MP12	NA	qRT-PCR	Decrease (50 %)	Approved, Investigational	27654301
DrugRepV_3624	Benzodiazepine	Nervous System	Obesity, Sleep Apnea, Obstructive, and Disorders of Gallbladder, Biliary Tract and Pancrease.	Severe acute respiratory syndrome coronavirus	Toronto-2	NA	qRT-PCR	Decrease (50 %)	Approved, Investigational	27654301
DrugRepV_3625	Benzodiazepine	Nervous System	Obesity, Sleep Apnea, Obstructive, and Disorders of Gallbladder, Biliary Tract and Pancrease.	Influenza virus	Influenza A/California/7/2009		qRT-PCR	Decrease (50 %)	Approved, Investigational	27654301
DrugRepV_3626	Benzodiazepine	Nervous System	Obesity, Sleep Apnea, Obstructive, and Disorders of Gallbladder, Biliary Tract and Pancrease.	Zika virus	Zika-016	NA	qRT-PCR	Decrease (50 %)	Approved, Investigational	27654301
DrugRepV_3933	IHVR-19029	NA	NA	Zika virus	PRVABC-59	NA	qRT-PCR	Decrease (50 %)	NA	29253498
DrugRepV_3951	Favipiravir	Antiviral	Influenza virus	Marburg virus	NA	NA	qRT-PCR	Decrease (50 %)	Investigational	29369776
DrugRepV_3952	Favipiravir	Antiviral	Influenza virus	Marburg virus	NA	NA	qRT-PCR	Decrease	Investigational	29369776
DrugRepV_4141	5-ethyl-3-{3-[(1E)-1-(methoxyimino)ethyl]phenyl}-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	Venturini	NA	qRT-PCR	Decrease (50 %)	NA	28619679
DrugRepV_4142	5-ethyl-3-{3-[(1E)-1-{[2-(morpholin-4-yl)ethoxy]imino}ethyl]phenyl}-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	Venturini	NA	qRT-PCR	Decrease (50 %)	NA	28619679
DrugRepV_4143	5-ethyl-3-{3-[(1E)-1-{[2-(piperidin-1-yl)ethoxy]imino}ethyl]phenyl}-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	Venturini	NA	qRT-PCR	Decrease (50 %)	NA	28619679
DrugRepV_4144	5-ethyl-3-{3-[(1E)-1-(methoxyimino)ethyl]phenyl}-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	Congo 95	NA	qRT-PCR	Decrease (50 %)	NA	28619679
DrugRepV_4145	5-ethyl-3-{3-[(1E)-1-{[2-(morpholin-4-yl)ethoxy]imino}ethyl]phenyl}-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	Congo 95	NA	qRT-PCR	Decrease (50 %)	NA	28619679
DrugRepV_4146	5-ethyl-3-{3-[(1E)-1-{[2-(piperidin-1-yl)ethoxy]imino}ethyl]phenyl}-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	Congo 95	NA	qRT-PCR	Decrease (50 %)	NA	28619679
DrugRepV_4147	5-ethyl-3-{3-[(1E)-1-(methoxyimino)ethyl]phenyl}-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	St. Martin 20235	NA	qRT-PCR	Decrease (50 %)	NA	28619679
DrugRepV_4148	5-ethyl-3-{3-[(1E)-1-{[2-(piperidin-1-yl)ethoxy]imino}ethyl]phenyl}-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	St. Martin 20235	NA	qRT-PCR	Decrease (50 %)	NA	28619679
DrugRepV_5386	Quinacrine	NA	Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions	Ebola virus	NA	NA	qRT-PCR	Decrease	Investigational	31307979
DrugRepV_5473	Remdesivir	Antiviral	Hepatitis C | Ebola	SARS Coronavirus-2	nCoV- 2019BetaCoV/Wuhan/WIV04/2019	NA	qRT-PCR	Decrease (50 %)	Experimental	32020029
DrugRepV_5474	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	SARS Coronavirus-2	nCoV- 2019BetaCoV/Wuhan/WIV04/2019	NA	qRT-PCR	Decrease (50 %)	Approved	32020029
DrugRepV_5475	Penciclovir	Antiinfectives For Systemic Use	Recurrent cold sores on the lips and face from Herpesvirus invections	SARS Coronavirus-2	nCoV- 2019BetaCoV/Wuhan/WIV04/2019	NA	qRT-PCR	Decrease (50 %)	Approved	32020029
DrugRepV_5476	Nitazoxanide	Antiparasitic products, Insectisides and Repellents	Diarrhea	SARS Coronavirus-2	nCoV- 2019BetaCoV/Wuhan/WIV04/2019	NA	qRT-PCR	Decrease (50 %)	Approved, Investigational, Vet approved	32020029
DrugRepV_5477	Nafamostat	NA	Blood vessel coagulation | Hemorrhagic lesions	SARS Coronavirus-2	nCoV- 2019BetaCoV/Wuhan/WIV04/2019	NA	qRT-PCR	Decrease (50 %)	Investigational	32020029
DrugRepV_5478	Favipiravir	Antiviral	Influenza virus	SARS Coronavirus-2	nCoV- 2019BetaCoV/Wuhan/WIV04/2019	NA	qRT-PCR	Decrease (50 %)	Investigational	32020029
DrugRepV_5483	RK-33	NA	NA	Zika virus	Asian/Cook Islands/2014	NA	qRT-PCR	Decrease (50 %)	NA	31936642
DrugRepV_5503	Cepharanthine	Antiinflammatory and antineoplastic	Inflammatory disorders/Cancer	SARS Coronavirus-2	GX_P2V/pangolin/2017/Guangxi	NA	qRT-PCR	Decrease (50 %)	NA	32149769
DrugRepV_5504	Selamectin	Antiparasitic	Vet-Antihelminthic	SARS Coronavirus-2	GX_P2V/pangolin/2017/Guangxi	NA	qRT-PCR	Decrease	Vet approved	32149769
DrugRepV_5505	Mefloquine hydrochloride	Antiparasitic products, Insectisides and Repellents	Malaria	SARS Coronavirus-2	GX_P2V/pangolin/2017/Guangxi	NA	qRT-PCR	Decrease	Approved, Investigational	32149769
DrugRepV_6063	Benzodiazepine	Nervous System	Obesity, Sleep Apnea, Obstructive, and Disorders of Gallbladder, Biliary Tract and Pancrease.	Dengue virus	DENV-2 New guinea C		qRT-PCR	Decrease (90 %)	Phase I	27654301
DrugRepV_6096	Doxorubicin	Antineoplastic and Immunomodulating Agents	Cancer	Dengue virus	New Guinea C (NGC)		qRT-PCR	Decrease (50 %)	Approved	20837762
DrugRepV_6097	SA-3	NA	NA	Dengue virus	New Guinea C (NGC)		qRT-PCR	Decrease (50 %)	NA	20837762
DrugRepV_6098	SA-11	NA	NA	Dengue virus	New Guinea C (NGC)		qRT-PCR	Decrease (50 %)	NA	20837762
DrugRepV_6099	SA-17	NA	NA	Dengue virus	New Guinea C (NGC)		qRT-PCR	Decrease (50 %)	NA	20837762
DrugRepV_6100	SA-17	NA	NA	Dengue virus	New Guinea C		qRT-PCR	Decrease (50 %)	NA	20837762
DrugRepV_6106	IHVR-19029	NA	NA	Dengue virus	NA		qRT-PCR	Decrease (50 %)	NA	29253498
DrugRepV_6150	AR-12	NA	Solid Tumors and Lymphoma	Dengue virus	NA		qRT-PCR	Decrease	Phase I	28666323
DrugRepV_6151	AR-12	NA	Solid Tumors and Lymphoma	Dengue virus	NA		qRT-PCR	Decrease	Phase I	28666323
DrugRepV_6152	AR-12	NA	Solid Tumors and Lymphoma	Dengue virus	NA		qRT-PCR	Decrease	Phase I	28666323
DrugRepV_6153	AR-12	NA	Solid Tumors and Lymphoma	Dengue virus	NA		qRT-PCR	Decrease	Phase I	28666323
DrugRepV_6154	Schisandrin A	NA	NA	Dengue virus	NA		qRT-PCR	Decrease (50 %)	NA	28338050
DrugRepV_6155	Schisandrin B	NA	NA	Dengue virus	NA		qRT-PCR	Decrease (50 %)	NA	28338050
DrugRepV_6156	Schisandrin C	NA	NA	Dengue virus	NA		qRT-PCR	Decrease (50 %)	NA	28338050
DrugRepV_7170	Benzodiazepine	Nervous System	Obesity, Sleep Apnea, Obstructive, and Disorders of Gallbladder, Biliary Tract and Pancrease.	West Nile virus	KERN515 WN02		qRT-PCR	Decrease (50 %)	Phase I	27654301
DrugRepV_7171	Benzodiazepine	Nervous System	Obesity, Sleep Apnea, Obstructive, and Disorders of Gallbladder, Biliary Tract and Pancrease.	Japanese encephalitis virus	SA14		qRT-PCR	Decrease (50 %)	Phase I	27654301
DrugRepV_7172	Benzodiazepine	Nervous System	Obesity, Sleep Apnea, Obstructive, and Disorders of Gallbladder, Biliary Tract and Pancrease.	Yellow fever virus	17D		qRT-PCR	Decrease (50 %)	Phase I	27654301
DrugRepV_7206	CCG-4088	NA	NA	Yellow fever virus	YFV 17D		qRT-PCR	Decrease (20 Fold)	NA	19651907
DrugRepV_7207	CCG-3394	NA	NA	Yellow fever virus	YFV 17D		qRT-PCR	Decrease (15 Fold)	NA	19651907
DrugRepV_7216	Doxorubicin	Antineoplastic and Immunomodulating Agents	Cancer	Yellow fever virus	17D		qRT-PCR	Decrease (50 %)	Approved	20837762
DrugRepV_7217	SA-3	NA	NA	Yellow fever virus	17D		qRT-PCR	Decrease (50 %)	NA	20837762
DrugRepV_7218	SA-11	NA	NA	Yellow fever virus	17D		qRT-PCR	Decrease (50 %)	NA	20837762
DrugRepV_7219	SA-17	NA	NA	Yellow fever virus	17D		qRT-PCR	Decrease (50 %)	NA	20837762
DrugRepV_7220	SA-17	NA	NA	Yellow fever virus	17D		qRT-PCR	Decrease (50 %)	NA	20837762
DrugRepV_7242	IHVR-19029	NA	NA	Yellow fever virus	17D		qRT-PCR	Decrease (50 %)	NA	29253498
DrugRepV_7782	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	SARS Coronavirus-2	nCoV-2019BetaCoV/Wuhan/WIV04/2019	NA	qRT-PCR	Decrease (50 %)	Approved	32194981
DrugRepV_7783	Hydroxychloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	SARS Coronavirus-2	nCoV-2019BetaCoV/Wuhan/WIV04/2019	NA	qRT-PCR	Decrease (50 %)	Approved	32194981
DrugRepV_7786	Suramin	Antiparasitic products, Insectisides and Repellents	Sleeping sickness | Onchocerciasis	SARS Coronavirus-2	SARS-CoV-2/Leiden-0002	NA	qRT-PCR	Decrease (50 %)	Investigational	32513797
DrugRepV_7787	Auranofin	Musculo-Skeletal System	Rheumatoid arthritis	SARS Coronavirus-2	USA-WA1/2020	NA	qRT-PCR	Decrease (50 %)	Approved	32442105
DrugRepV_8275	Digoxin	Cardiovascular agents	Arrhythmia	Zika virus	NA	NA	qRT-PCR	Decrease (50 %)	Approved	32669655
DrugRepV_8276	Ouabain	Cardiovascular agents	Atrial fibrillation and flutter | Heart failure	Zika virus	NA	NA	qRT-PCR	Decrease (50 %)	Approved	32669655